Cathie Woods Strikes Again 🎯

Cathie Woods Strikes Again 🎯 Is The Resurgence Of Growth Stocks Upon Us? 

If your investment journey kicked off during the COVID chaos, chances are ARK Invest was like the cool kid at the investing party. Sadly, it might've been the one that played with your heartstrings and left you with some investment battle scars.

Picture this: Retail investors flocked to Cathie Wood's tech-centric ETFs like moths to a flame during the pandemic frenzy. ARK Innovation ETF (NYSEARCA:ARKK), the crown jewel, skyrocketed nearly 212% from the pandemic dawn to mid-2021.

But oh, the saga of the Investors of the Lost ARK unfolded when the Fed decided to play the interest rate card. The growth stock empire crumbled faster than a house of cards in a windstorm, and ARKK took an 82% nosedive from its glorious peak.

But hey, in the unpredictable world of investing, every fall is just a setup for a comeback. ARK didn't just bounce back; it danced back with its best month ever in November, scoring a 31% gain. Growth stocks were back on the stage, and ARKK was up 59% for the year.

November saw the dynamic duo of Coinbase (NASDAQ:COIN) and Roku (NASDAQ:ROKU), ARK's heavyweight champions, pulling off a performance that would make any investor's heart skip a beat—62% and 75% gains, respectively.

Now, despite this November fiesta, most ARK investors might still be swimming in the red. The fund is down around 70% from its glory days, desperately trying to reclaim its former Wall Street rockstar status.

Where's ARK headed next? Well, it seems like analysts are sipping on some optimism juice for growth stocks, predicting a potential rise in 2024, especially with some fancy anticipated rate cuts. Even Deutsche Bank is waving the "US growth stocks are the way to go" banner after 2023's stock market rollercoaster.

Now, let's talk genomics—the secret sauce in ARK's investment mix. CRISPR Therapeutics (NASDAQ:CRSP) and Twist Bioscience (NASDAQ:TWST) did a victory lap with the UK's nod for the first CRISPR therapy. ARK's COO, Tom Staudt, is all about that genomics life, saying they've got a "meaningful amount of genomics exposure." With CRISPR therapies knocking on the FDA's door on Dec. 8, it's like waiting for the sequel to a blockbuster—game-changing medicine and the companies making it happen.

So, buckle up, fellow investors! The ARK saga continues, and the genomics frontier is calling. Will ARK rise from the depths? Only time, and maybe a sprinkle of investing magic, will tell.

Keep riding the ARK waves, my friends! 🚀💼

TODAYS HOT RUNNERS ON WATCH 🚀

$MLGO +150% MicroAlgo (MLGO) develops and delivers central processing algorithm solutions to customers in internet advertisement, gaming, and intelligent chip industries in the People's Republic of China 🔥

$SERA +250% Sera Prognostics Says Study of Preterm Birth Prevention Strategy Met Primary Endpoint Criteria; Shares Surge🔥 

Hey guys, we’ve been on a hot streak and our last swing pick generated ALMOST 26+% 🔥 

Did you get it?

If not, keep reading… 👇🏽

Over the past 150 trades, we boast a 81% success rate for our premium members! With the Bullseye Trades premium membership, we streamline stock selection, consistently offering fresh stock picks and insights to simplify the process for our members. As a premium subscriber, you gain instant access to the swing trades that we are actively taking allowing you to minimize the time spent navigating the complexities of the market and focus more on doing what you love to do.

Here are the last 5 swing trades we recently closed 🎯 

Our next alert is going out later today, don’t miss it 🤝 Click below to join 👇🏽

From your’s truly 👋🏼